DDInter1763 DDInter1676
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
Temsirolimus {u} (Compound) upregulates {v} (Gene) MICU1
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Temsirolimus {u} (Compound) downregulates {v} (Gene) TFDP1
Temsirolimus {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Temsirolimus (Compound) resembles Everolimus (Compound)
Temsirolimus (Compound) treats kidney cancer (Disease)
Temsirolimus (Compound) binds CYP3A4 (Gene)
Temsirolimus (Compound) upregulates MICU1 (Gene)
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Temsirolimus (Compound) downregulates TFDP1 (Gene)
Temsirolimus (Compound) causes Febrile neutropenia (Side Effect)